SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-032021
Filing Date
2023-09-12
Accepted
2023-09-12 07:10:53
Documents
15
Period of Report
2023-09-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20230911.htm   iXBRL 8-K 34667
2 EX-2.1 ex21-augxavaloxapa37359809.htm EX-2.1 271712
3 EX-99.1 ex-991avaloentersintoagree.htm EX-99.1 13636
7 avalo-logoxblk1a.jpg GRAPHIC 99614
  Complete submission text file 0001628280-23-032021.txt   639757

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20230911.xsd EX-101.SCH 1969
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20230911_lab.xml EX-101.LAB 24183
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20230911_pre.xml EX-101.PRE 12576
9 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20230911_htm.xml XML 2625
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 231249000
SIC: 2834 Pharmaceutical Preparations